Shares of Novo Nordisk A/S fell after the Danish drugmaker reported mixed safety data on one of its next-generation weight-loss drugs.

Novo Nordisk and Eli Lilly are offering discounts to encourage more insurance coverage of the medicines, which carry price tags of over $1,000 a month.

Meaning, whether you lose weight through a change in your diet, a different medication, or bariatric surgery, there is a risk of losing bone density. However, in this particular study, taking weight loss drugs like Ozempic did seem to have a bigger impact on bone density than losing weight through other means.

F ROM LOS ANGELES to London, weight-loss drugs such as Ozempic are reshaping culture as much as waistlines. Some Ozempic-takers have tiny appetites and dine at unusual hours to avoid spells of nausea.

Many people are doing an end-run around their doctor's office, reaching out to potentially unreliable sources that promise to set them up with Wegovy, Zepbound and other weight-loss drugs.

A next-generation obesity drug candidate from Novo Nordisk produced modest weight loss, along with a higher rate of some psychiatric side effects, new data show.